Preclinical research supporting use of oral anti-TNFα Vorabody V565 in IBD treatment published in *Scientific Reports*

First full account of V565 preclinical development available in open access journal

Cambridge, UK, March 21 2018 – Preclinical studies supporting the concept and feasibility of oral dosing with anti-TNFα Vorabody V565 in inflammatory bowel disease (IBD) have been published in *Scientific Reports*. This is the first comprehensive report of the data backing the clinical development of V565, a domain antibody engineered for protease resistance and oral delivery by VHsquared, the oral domain antibody company. V565 is the lead Vorabody in the company's IBD-focused portfolio and is in an international Phase II trial for Crohn's disease, HarbOR (V56502).

'*Preclinical Development of a Novel, Orally-Administered Anti-Tumour Necrosis Factor Domain Antibody for the Treatment of Inflammatory Bowel Disease'* describes the preclinical development of V565, demonstrating its high protease resistance, transit through the entire mouse GI tract, and detection at the site of disease in DSS colitis mice. Evidence that V565 crosses the lamina propria, and of anti-inflammatory activity in a human IBD biopsy model, are also discussed. The work was carried out by VHsquared, the Wellcome Sanger Institute, RxCelerate and the Blizard Institute (Barts and the London School of Medicine, Queen Mary University of London).

Vorabodies are potent, orally administered protease-resistant domain antibodies generated by VHsquared's pioneering platform technology. V565 has been developed to achieve optimum local concentrations directly at IBD sites in the intestinal tract. It is expected to combine the disease modifying impact of injectable systemic anti-TNFα antibodies in IBD with the benefits of oral administration, with activity targeted to the site of inflammation, negligible systemic exposure and minimal immunogenicity.

---ENDS---

For more information please contact scott.crowe@vhsquared.com